British pharmaceutical giant and frontrunner in the race for a COVID-19 vaccine, AstraZeneca has resumed its Phase 3 trials in the U.S.
The clinical trials came into question last month when a participant in the UK fell ill with a serious neurological condition.
But with no link found between the trials and the illness, the leading developer said the U.S. Food and Drug Administration had reviewed all safety data and deemed it safe to continue testing the vaccine for now.
After a brief global suspension, the trials resumed in the U.K., Brazil, and South Africa last month despite the FDA conducting investigations at the time.
AstraZeneca is developing the vaccine in collaboration with researchers at Oxford University.